INTEGRATED BIOPHARMA, INC. (INBP) Operating margin 2018–2026
INTEGRATED BIOPHARMA, INC. (INBP) operating margin by fiscal year — reported operating income divided by reported revenue.
-6.2%FY2026 · since FY2018: 3.9% → -6.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -6.2% | -9.9 pp |
| FY2025 | 3.7% | +3.2 pp |
| FY2024 | 0.5% | +0.3 pp |
| FY2023 | 0.2% | -4.6 pp |
| FY2022 | 4.9% | -4.2 pp |
| FY2021 | 9.1% | +2.9 pp |
| FY2020 | 6.2% | +0.8 pp |
| FY2019 | 5.4% | +1.5 pp |
| FY2018 | 3.9% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More INBP financial trends
INBP RevenueINBP Net incomeINBP Net marginINBP Gross profitINBP Gross marginINBP Operating incomeINBP Operating cash flowINBP Free cash flowINBP Capital expendituresINBP Return on equityINBP Stock buybacksINBP Dividends paidINBP Total assetsINBP Total liabilitiesINBP Shareholders’ equityINBP overview →